Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination.
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
Clinically meaningful performance benchmarks in MS: Timed 25-Foot Walk and the real world.
A hematopoietic contribution to microhemorrhage formation during antiviral CD8 T cell-initiated blood-brain barrier disruption.
Multiple sclerosis.
Citrullination of Histone H3 Interferes with HP1-Mediated Transcriptional Repression.
Effects of phenytoin on the persistent Na+ current of mammalian CNS neurones.
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)
[Clinical validity of the quantitative gait variables in patients with multiple sclerosis. A comparison of the Timed 25-foot Walk Test and the GAITRite ® Electronic Walkway system].
17β-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone, contributes to neurodegeneration.
Long-term Analyses of Innervation and Neuromuscular Integrity in the Trembler-J Mouse Model of Charcot-Marie-Tooth Disease.
Biomarkers in Multiple Sclerosis: An Up-to-Date Overview.
Regulation of encephalitogenicity of neuroantigen-primed T cells by nitric oxide: Implications for multiple sclerosis.
Substance Name: MEDI 551
Torque teno mini virus infection and multiple sclerosis.
[2012: Update on diagnosis and treatment of multiple sclerosis].
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonb therapy in multiple sclerosis.
Diagnosis and treatment of pediatric acute transverse myelitis.
Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI?
Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.
Inpatient Rehabilitation Utilization for Medicare Beneficiaries with Multiple Sclerosis.
[Gluten-related disorders and demyelinating diseases.]
Metals and Neurodegeneration.
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation.

Pages